Asset profile
Sarilumab
Monoclonal antibody
Evidence outlook
Approved: Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 58 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Sarilumab: this drug | Approved | Monoclonal antibody | IL-6 receptor | ||
| Tocilizumab (Actemra / RoActemra) | Approved | Monoclonal antibody | IL-6 receptor, IL-6R antagonist | ||
| Levilimab | Phase 3 | Monoclonal antibody | IL-6 receptor | ||
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | ||
| Adalimumab-Ryvk (Simlandi) | Approved | — | TNF-alpha | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Anakinra (r-metHuIL-1ra) | Approved | Protein / enzyme therapeutic | Interleukin-1 receptor (IL-1R), Interleukin-1 receptor type 1 (IL-1R1) | ||
| Baricitinib (Olumiant) | Approved | Small molecule | JAK, JAK1/2 | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| CT-P13 (Inflectra / Remsima) | Approved | Monoclonal antibody | TNF-alpha | ||
| CT-P47 (tocilizumab) (Avtozma) | Approved | Monoclonal antibody | IL-6R antagonist | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(13 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
November 2026 (1)
What to watch
2027 (2)
January 2027 (1)
What to watch
May 2027 (1)
What to watch
2028 (7)
January 2028 (1)
What to watch
March 2028 (2)
May 2028 (1)
June 2028 (1)
What to watch
October 2028 (1)
What to watch
November 2028 (1)
What to watch
2029 (1)
June 2029 (1)
What to watch
2030 (2)
June 2030 (1)
What to watch
December 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.